Latest filing published 06 Mar 2026 for Madrigal Pharmaceuticals, INC., €183k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +105.9%Entry 0.14 · Close at T+365 0.28
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Rebecca Taub: trading record in brief
This profile gathers the share dealings of Rebecca Taub across 2 companies, led by Madrigal Pharmaceuticals, Inc. and Corautus Genetics Inc. Over a trading history stretching from 5 December 2008 to 6 March 2026, the count stands at 115 filings.
Both buying and selling appear: 1 purchase worth €7,667, against 92 sales worth €77.7M. Taken together, the sales exceed the purchases by €77.7M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 9 share grants and 12 option exercises. So far in 2026, the count stands at no purchases and 33 sales.
The latest filing, published on 6 March 2026, reports an open-market sale of €183k in Madrigal Pharmaceuticals, Inc. The most recent open-market purchase was published on 19 December 2008, 6,533 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Rebecca Taub
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 491 shares@ US$431.945.3% of flowCommon StockSEC:0001628280-26-015736:0
- 647 shares@ US$492.427.9% of flowCommon StockSEC:0001628280-26-003452:0
- 2,238 shares@ US$490.7727.6% of flowCommon StockSEC:0001628280-26-002735:0
- 40 shares@ US$545.790.0% of flowCommon StockSEC:0001628280-26-001970:1
- 200 shares@ US$551.240.1% of flowCommon StockSEC:0001628280-26-001970:2
- 960 shares@ US$512.020.5% of flowCommon StockSEC:0001628280-26-001961:1
- 960 shares@ US$513.120.5% of flowCommon StockSEC:0001628280-26-001961:2
- 937 shares@ US$514.630.5% of flowCommon StockSEC:0001628280-26-001961:3
- 1,578 shares@ US$515.820.9% of flowCommon StockSEC:0001628280-26-001961:4
- 521 shares@ US$516.810.3% of flowCommon StockSEC:0001628280-26-001961:5
- 2,044 shares@ US$517.841.1% of flowCommon StockSEC:0001628280-26-001961:6
- 970 shares@ US$518.670.5% of flowCommon StockSEC:0001628280-26-001961:7
- 539 shares@ US$519.890.3% of flowCommon StockSEC:0001628280-26-001961:8
- 440 shares@ US$521.110.2% of flowCommon StockSEC:0001628280-26-001961:9
- 588 shares@ US$521.950.3% of flowCommon StockSEC:0001628280-26-001961:10
- 732 shares@ US$522.980.4% of flowCommon StockSEC:0001628280-26-001961:11
- 1,335 shares@ US$524.060.8% of flowCommon StockSEC:0001628280-26-001961:12
- 1,489 shares@ US$525.120.8% of flowCommon StockSEC:0001628280-26-001961:13
- 913 shares@ US$526.050.5% of flowCommon StockSEC:0001628280-26-001961:14
- 1,135 shares@ US$526.950.6% of flowCommon StockSEC:0001628280-26-001961:15
- 465 shares@ US$528.160.3% of flowCommon StockSEC:0001628280-26-001961:16
- 554 shares@ US$529.280.3% of flowCommon StockSEC:0001628280-26-001961:17
- 256 shares@ US$530.450.1% of flowCommon StockSEC:0001628280-26-001961:18
- 30 shares@ US$531.050.0% of flowCommon StockSEC:0001628280-26-001961:19
- 40 shares@ US$532.500.0% of flowCommon StockSEC:0001628280-26-001961:20
25 of 115 declarations
